3X Genetics

Executive Summary

3X Genetics is a US-based commercial-stage diagnostics company leveraging advanced genomics and sequencing technologies to identify genetic markers for disease risk and progression. Founded in 2020 and headquartered in San Diego, the company focuses on oncology, cardiovascular, and pharmacogenomic applications. By providing actionable insights from genetic data, 3X Genetics aims to enable preventive care and personalized treatment strategies, addressing the growing demand for precision medicine. With a team of 50-200 employees and a commercial product portfolio, the company is positioned to capture value in the expanding $50+ billion global genetic testing market. Its integrated platform combines high-throughput sequencing, proprietary algorithms, and clinical interpretation to deliver high-accuracy results, differentiating it from competitors. Recent momentum includes expansion of its test menu and partnerships with healthcare providers, driving revenue growth. 3X Genetics is well-poised to benefit from rising adoption of genetic screening in oncology and cardiovascular disease, as well as increasing reimbursement coverage. The company's focus on actionable, affordable diagnostics positions it for sustained growth in the precision health sector. Key near-term catalysts include new product launches and potential FDA clearances that could expand its addressable market and validate its technology platform.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance for a cardiovascular risk assessment test80% success
• Q3 2026Launch of an expanded pharmacogenomic panel70% success
• Q1 2027Partnership with a major health system for oncology diagnostics60% success